Kim Hye In, Kim Tae Hyuk, Kim Hosu, Kim Sun Wook, Hahm Jong Ryeal, Chung Jae Hoon
Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
Department of Medicine, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
Thyroid. 2023 Jan;33(1):100-108. doi: 10.1089/thy.2022.0216. Epub 2023 Jan 4.
Hypothyroidism is a risk factor for dyslipidemia. We explored whether dyslipidemia is a risk factor for hypothyroidism. We performed a retrospective analysis of data from a longitudinal cohort study of South Korean adults who underwent medical examination and ≥4 biochemical assessments of thyroid function. The primary outcome was hypothyroidism (thyrotropin [TSH] >4.2 mU/L), and the secondary outcome was severe subclinical hypothyroidism (SCH; TSH ≥10.0 mU/L and normal free thyroxine [fT4] level) or overt hypothyroidism (OH; total triiodothyronine <80 ng/dL and/or fT4 < 0.93 ng/dL and high TSH values). The association of baseline dyslipidemia status with subsequent hypothyroidism was evaluated using Kaplan-Meier curves with the log-rank test and Cox proportional hazards regression models (for the entire population and respective genders). Subgroup analyses according to age (<40 and ≥40 years) and body-mass index (BMI; <23, 23-25, and ≥25 kg/m) were performed according to gender. We included 1665 participants. During a median follow-up period of 61.0 months, 24.3% (404/1665) individuals developed hypothyroidism. Among these, 36 participants (2.1%) had severe SCH or OH. Excluding patients with a first abnormal TSH level at last follow-up, 44.5% (126/283) of the patients with hypothyroidism had spontaneous TSH normalization. In respective multivariate analyses, dyslipidemia at baseline was independently associated with development of hypothyroidism in women (adjusted hazard ratio [HR] = 2.05 [1.31-3.19], = 0.002), but not in men (adjusted HR = 1.00 [0.77-1.30], = 0.991). In women, the presence of dyslipidemia at baseline was associated with development of severe SCH or OH (adjusted HR = 5.33 [1.41-20.12], = 0.014). In women, respective associations according to age and BMI were as follows: age <40 years, adjusted HR = 2.90 (1.34-6.26, = 0.007); age ≥40 years, adjusted HR = 1.85 (1.08-3.14, = 0.023); BMI <23 kg/m, adjusted HR = 1.68 (0.82-3.43, = 0.151); BMI = 23-25 kg/m, adjusted HR = 2.17 (0.93-5.07, = 0.071); and BMI ≥25 kg/m, adjusted HR = 2.82 (1.16-6.86, = 0.022). In Korean adults, dyslipidemia was associated with development of hypothyroidism in women. Our findings require confirmation.
甲状腺功能减退是血脂异常的一个危险因素。我们探讨了血脂异常是否为甲状腺功能减退的危险因素。我们对韩国成年人纵向队列研究的数据进行了回顾性分析,这些成年人接受了医学检查以及≥4次甲状腺功能的生化评估。主要结局是甲状腺功能减退(促甲状腺激素[TSH]>4.2 mU/L),次要结局是严重亚临床甲状腺功能减退(SCH;TSH≥10.0 mU/L且游离甲状腺素[fT4]水平正常)或显性甲状腺功能减退(OH;总三碘甲状腺原氨酸<80 ng/dL和/或fT4<0.93 ng/dL且TSH值升高)。使用Kaplan-Meier曲线和对数秩检验以及Cox比例风险回归模型(针对整个人群和各性别)评估基线血脂异常状态与随后甲状腺功能减退的关联。根据年龄(<40岁和≥40岁)和体重指数(BMI;<23、23 - 25和≥25 kg/m²)进行亚组分析,并按性别分组。我们纳入了1665名参与者。在中位随访期61.0个月期间,24.3%(404/1665)的个体发生了甲状腺功能减退。其中,36名参与者(2.1%)患有严重SCH或OH。排除最后随访时首次出现TSH水平异常的患者后,44.5%(126/283)的甲状腺功能减退患者TSH自发恢复正常。在各自的多变量分析中,基线血脂异常与女性甲状腺功能减退的发生独立相关(调整后风险比[HR]=2.05[1.31 - 3.19],P = 0.002),但与男性无关(调整后HR = 1.00[0.77 - 1.30],P = 0.991)。在女性中,基线血脂异常与严重SCH或OH的发生相关(调整后HR = 5.33[1.41 - 20.12],P = 0.014)。在女性中,根据年龄和BMI的各自关联如下:年龄<40岁,调整后HR = 2.90(1.34 - 6.26,P = 0.007);年龄≥40岁,调整后HR = 1.85(1.08 - 3.14,P = 0.023);BMI<23 kg/m²,调整后HR = 1.68(0.82 - 3.43,P = 0.151);BMI = 23 - 25 kg/m²,调整后HR = 2.17(0.93 - 5.07,P = 0.071);BMI≥25 kg/m²,调整后HR = 2.82(1.16 - 6.86,P = 0.022)。在韩国成年人中,血脂异常与女性甲状腺功能减退的发生相关。我们的研究结果需要进一步证实。